| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipoproteinemia Type II | 25 | 2019 | 111 | 4.110 |
Why?
|
| Hypertension | 95 | 2023 | 1348 | 3.190 |
Why?
|
| Triglycerides | 32 | 2016 | 614 | 1.800 |
Why?
|
| Coronary Disease | 25 | 2011 | 682 | 1.700 |
Why?
|
| Genotype | 41 | 2021 | 2717 | 1.370 |
Why?
|
| Blood Pressure | 39 | 2023 | 1379 | 1.240 |
Why?
|
| Aldosterone | 17 | 2022 | 60 | 1.180 |
Why?
|
| Cholesterol, HDL | 30 | 2020 | 393 | 1.130 |
Why?
|
| Lipoproteins | 10 | 2014 | 191 | 1.110 |
Why?
|
| Apolipoproteins B | 12 | 2019 | 146 | 1.070 |
Why?
|
| Middle Aged | 178 | 2023 | 29020 | 1.060 |
Why?
|
| Fenofibrate | 11 | 2018 | 61 | 1.060 |
Why?
|
| Coronary Artery Disease | 16 | 2020 | 890 | 1.060 |
Why?
|
| Polymorphism, Single Nucleotide | 34 | 2023 | 2857 | 1.050 |
Why?
|
| Sodium Chloride, Dietary | 14 | 2023 | 37 | 1.020 |
Why?
|
| Cholesterol, LDL | 23 | 2019 | 600 | 1.020 |
Why?
|
| Hyperlipidemias | 12 | 2016 | 188 | 1.000 |
Why?
|
| Proprotein Convertase 9 | 6 | 2019 | 82 | 0.950 |
Why?
|
| Calcinosis | 9 | 2015 | 190 | 0.900 |
Why?
|
| Genetic Linkage | 23 | 2015 | 481 | 0.880 |
Why?
|
| Adult | 145 | 2025 | 31742 | 0.870 |
Why?
|
| Lipids | 16 | 2018 | 562 | 0.860 |
Why?
|
| Cholesterol | 18 | 2020 | 565 | 0.780 |
Why?
|
| Hypertrophy, Left Ventricular | 16 | 2009 | 112 | 0.750 |
Why?
|
| Gain of Function Mutation | 2 | 2019 | 116 | 0.740 |
Why?
|
| Insulin Resistance | 15 | 2020 | 699 | 0.740 |
Why?
|
| Humans | 245 | 2025 | 133202 | 0.720 |
Why?
|
| Utah | 35 | 2021 | 83 | 0.720 |
Why?
|
| Aged | 94 | 2021 | 21480 | 0.700 |
Why?
|
| Angiotensinogen | 8 | 2021 | 24 | 0.680 |
Why?
|
| Female | 195 | 2025 | 71456 | 0.680 |
Why?
|
| Pedigree | 38 | 2013 | 1731 | 0.680 |
Why?
|
| Cacao | 2 | 2010 | 8 | 0.680 |
Why?
|
| Male | 186 | 2022 | 65411 | 0.680 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2019 | 558 | 0.620 |
Why?
|
| Hypolipidemic Agents | 9 | 2015 | 188 | 0.620 |
Why?
|
| Metabolic Syndrome | 10 | 2017 | 365 | 0.600 |
Why?
|
| Lipoproteins, LDL | 8 | 2016 | 137 | 0.580 |
Why?
|
| Receptors, LDL | 12 | 2017 | 103 | 0.570 |
Why?
|
| Polymorphism, Genetic | 15 | 2017 | 810 | 0.570 |
Why?
|
| Ultracentrifugation | 2 | 2015 | 23 | 0.560 |
Why?
|
| Sodium, Dietary | 10 | 2014 | 37 | 0.560 |
Why?
|
| Dietary Fats | 8 | 2020 | 296 | 0.550 |
Why?
|
| Renin | 16 | 2020 | 87 | 0.550 |
Why?
|
| Hypercholesterolemia | 7 | 2017 | 233 | 0.550 |
Why?
|
| Hyperlipoproteinemia Type III | 2 | 2014 | 2 | 0.540 |
Why?
|
| Hypertriglyceridemia | 8 | 2016 | 113 | 0.540 |
Why?
|
| Risk Factors | 51 | 2020 | 10935 | 0.540 |
Why?
|
| Cardiovascular Diseases | 13 | 2017 | 2066 | 0.540 |
Why?
|
| Coronary Vessels | 4 | 2015 | 536 | 0.530 |
Why?
|
| Renin-Angiotensin System | 10 | 2012 | 106 | 0.530 |
Why?
|
| Angiotensin II | 13 | 2020 | 158 | 0.520 |
Why?
|
| Diet, Sodium-Restricted | 9 | 2021 | 18 | 0.500 |
Why?
|
| Body Mass Index | 27 | 2017 | 1714 | 0.490 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2014 | 3361 | 0.490 |
Why?
|
| Lipoproteins, HDL | 7 | 2020 | 117 | 0.490 |
Why?
|
| Diet | 10 | 2015 | 1169 | 0.460 |
Why?
|
| Mass Screening | 4 | 2017 | 832 | 0.460 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2015 | 294 | 0.460 |
Why?
|
| Regression Analysis | 12 | 2015 | 808 | 0.440 |
Why?
|
| Surgery, Plastic | 2 | 2014 | 104 | 0.440 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 152 | 0.430 |
Why?
|
| Obesity | 17 | 2023 | 2419 | 0.430 |
Why?
|
| Lipoproteins, VLDL | 6 | 2014 | 57 | 0.430 |
Why?
|
| Family Health | 13 | 2011 | 257 | 0.430 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2025 | 98 | 0.420 |
Why?
|
| Caveolin 1 | 3 | 2020 | 50 | 0.410 |
Why?
|
| Genetic Testing | 4 | 2017 | 1100 | 0.410 |
Why?
|
| Lod Score | 13 | 2015 | 128 | 0.410 |
Why?
|
| Atherosclerosis | 6 | 2013 | 996 | 0.410 |
Why?
|
| Carnitine O-Palmitoyltransferase | 3 | 2020 | 26 | 0.400 |
Why?
|
| Exercise | 7 | 2023 | 867 | 0.390 |
Why?
|
| Odds Ratio | 11 | 2016 | 1262 | 0.390 |
Why?
|
| Obesity, Morbid | 5 | 2017 | 214 | 0.380 |
Why?
|
| Creatinine | 3 | 2004 | 417 | 0.380 |
Why?
|
| Hand Strength | 6 | 2023 | 60 | 0.380 |
Why?
|
| Renal Plasma Flow | 4 | 2021 | 5 | 0.370 |
Why?
|
| Adrenal Glands | 4 | 2020 | 50 | 0.360 |
Why?
|
| Prevalence | 15 | 2020 | 2671 | 0.360 |
Why?
|
| Students, Medical | 2 | 2014 | 364 | 0.360 |
Why?
|
| Career Choice | 1 | 2013 | 163 | 0.360 |
Why?
|
| Gastric Bypass | 5 | 2017 | 81 | 0.360 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2025 | 334 | 0.350 |
Why?
|
| Chromosome Mapping | 14 | 2017 | 1118 | 0.350 |
Why?
|
| Ceramides | 3 | 2020 | 46 | 0.340 |
Why?
|
| Genome-Wide Association Study | 11 | 2021 | 1840 | 0.330 |
Why?
|
| Population Surveillance | 3 | 2013 | 416 | 0.320 |
Why?
|
| Insulin | 14 | 2017 | 1226 | 0.320 |
Why?
|
| Flavonoids | 1 | 2010 | 87 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 902 | 0.320 |
Why?
|
| Hemodynamics | 9 | 2023 | 857 | 0.320 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 2632 | 0.310 |
Why?
|
| Cholesterol, VLDL | 6 | 2012 | 17 | 0.310 |
Why?
|
| Aortic Valve Insufficiency | 4 | 2003 | 156 | 0.300 |
Why?
|
| Calmodulin-Binding Proteins | 3 | 2017 | 65 | 0.300 |
Why?
|
| Epigenesis, Genetic | 4 | 2022 | 766 | 0.290 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2010 | 154 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 2 | 5 | 2004 | 122 | 0.290 |
Why?
|
| Membrane Proteins | 6 | 2021 | 1605 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2020 | 742 | 0.280 |
Why?
|
| Aging | 7 | 2018 | 1273 | 0.280 |
Why?
|
| Cross-Sectional Studies | 16 | 2021 | 3748 | 0.280 |
Why?
|
| Aged, 80 and over | 23 | 2018 | 7164 | 0.280 |
Why?
|
| Heterozygote | 9 | 2017 | 729 | 0.270 |
Why?
|
| Particle Size | 5 | 2015 | 148 | 0.270 |
Why?
|
| Genetic Carrier Screening | 2 | 2001 | 72 | 0.270 |
Why?
|
| Heart | 2 | 2010 | 703 | 0.270 |
Why?
|
| Lipoprotein(a) | 4 | 1998 | 138 | 0.270 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2017 | 50 | 0.270 |
Why?
|
| Lipid Metabolism | 6 | 2016 | 387 | 0.270 |
Why?
|
| Mutation | 9 | 2017 | 6314 | 0.270 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 723 | 0.270 |
Why?
|
| Postprandial Period | 6 | 2016 | 91 | 0.260 |
Why?
|
| Phenotype | 26 | 2015 | 4571 | 0.260 |
Why?
|
| Heart Ventricles | 8 | 2013 | 786 | 0.260 |
Why?
|
| Fenfluramine | 2 | 2003 | 12 | 0.260 |
Why?
|
| United States | 23 | 2020 | 11658 | 0.260 |
Why?
|
| Case-Control Studies | 13 | 2014 | 3433 | 0.250 |
Why?
|
| Homocysteine | 3 | 1997 | 120 | 0.250 |
Why?
|
| Antihypertensive Agents | 6 | 2022 | 401 | 0.250 |
Why?
|
| Inflammation | 6 | 2016 | 1546 | 0.250 |
Why?
|
| Sodium-Bicarbonate Symporters | 1 | 2005 | 16 | 0.240 |
Why?
|
| Cohort Studies | 21 | 2021 | 5175 | 0.240 |
Why?
|
| Adipose Tissue | 6 | 2019 | 510 | 0.240 |
Why?
|
| Epigenomics | 2 | 2018 | 196 | 0.240 |
Why?
|
| Bilirubin | 4 | 2002 | 131 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2020 | 1408 | 0.240 |
Why?
|
| Interleukin-6 | 4 | 2012 | 438 | 0.240 |
Why?
|
| Deep Sedation | 1 | 2025 | 8 | 0.230 |
Why?
|
| Gene Frequency | 12 | 2016 | 750 | 0.230 |
Why?
|
| Histone Demethylases | 3 | 2022 | 43 | 0.230 |
Why?
|
| Hyperlipidemia, Familial Combined | 7 | 2005 | 8 | 0.230 |
Why?
|
| Multivariate Analysis | 11 | 2014 | 1456 | 0.230 |
Why?
|
| Hyperaldosteronism | 2 | 2020 | 16 | 0.230 |
Why?
|
| Health Status | 4 | 2012 | 411 | 0.230 |
Why?
|
| Young Adult | 16 | 2021 | 9973 | 0.230 |
Why?
|
| Conscious Sedation | 1 | 2025 | 62 | 0.220 |
Why?
|
| Thyroid Gland | 2 | 2021 | 116 | 0.220 |
Why?
|
| Arterial Pressure | 1 | 2025 | 121 | 0.220 |
Why?
|
| Genetic Variation | 10 | 2020 | 1594 | 0.220 |
Why?
|
| Logistic Models | 9 | 2016 | 1852 | 0.220 |
Why?
|
| Hyperemia | 2 | 2022 | 35 | 0.220 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2003 | 183 | 0.220 |
Why?
|
| Spouses | 3 | 2011 | 73 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2010 | 71 | 0.210 |
Why?
|
| Brachial Artery | 3 | 2023 | 42 | 0.210 |
Why?
|
| Genetic Loci | 2 | 2017 | 362 | 0.210 |
Why?
|
| Muscle, Skeletal | 4 | 2020 | 1038 | 0.210 |
Why?
|
| Epoxide Hydrolases | 1 | 2003 | 37 | 0.210 |
Why?
|
| Dyslipidemias | 4 | 2020 | 240 | 0.210 |
Why?
|
| Serotonin Agents | 1 | 2003 | 15 | 0.210 |
Why?
|
| Surveys and Questionnaires | 10 | 2014 | 3987 | 0.210 |
Why?
|
| Apolipoprotein B-100 | 3 | 2019 | 39 | 0.200 |
Why?
|
| DNA Methylation | 5 | 2018 | 1140 | 0.200 |
Why?
|
| Hypertension, Renal | 3 | 2021 | 36 | 0.200 |
Why?
|
| Adolescent | 26 | 2021 | 20594 | 0.200 |
Why?
|
| Oxidoreductases, N-Demethylating | 2 | 2012 | 11 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 541 | 0.200 |
Why?
|
| Models, Biological | 4 | 2003 | 1522 | 0.190 |
Why?
|
| Ventricular Function, Left | 8 | 2013 | 544 | 0.190 |
Why?
|
| Resuscitation | 1 | 2025 | 268 | 0.190 |
Why?
|
| Thyrotropin | 2 | 2021 | 62 | 0.190 |
Why?
|
| Kidney | 5 | 2014 | 1346 | 0.190 |
Why?
|
| Serine Endopeptidases | 3 | 2010 | 198 | 0.190 |
Why?
|
| Adiponectin | 2 | 2012 | 128 | 0.190 |
Why?
|
| Myocardial Infarction | 3 | 2007 | 1068 | 0.190 |
Why?
|
| CD36 Antigens | 3 | 2017 | 42 | 0.190 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2010 | 46 | 0.190 |
Why?
|
| Alleles | 9 | 2021 | 1693 | 0.190 |
Why?
|
| Endothelium, Vascular | 3 | 2022 | 499 | 0.180 |
Why?
|
| Hypotension | 1 | 2023 | 188 | 0.180 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2021 | 2 | 0.180 |
Why?
|
| Sodium | 7 | 2022 | 293 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 2 | 2015 | 905 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1053 | 0.180 |
Why?
|
| Estrogen Receptor beta | 1 | 2021 | 86 | 0.180 |
Why?
|
| Systole | 8 | 2005 | 202 | 0.170 |
Why?
|
| Regional Blood Flow | 4 | 2023 | 217 | 0.170 |
Why?
|
| Heart Arrest | 1 | 2025 | 375 | 0.170 |
Why?
|
| Estrogens | 2 | 2022 | 521 | 0.170 |
Why?
|
| Hypothyroidism | 1 | 2021 | 80 | 0.170 |
Why?
|
| Salivary alpha-Amylases | 1 | 2020 | 2 | 0.170 |
Why?
|
| Echocardiography, Doppler | 6 | 2013 | 173 | 0.170 |
Why?
|
| Follow-Up Studies | 12 | 2017 | 5448 | 0.170 |
Why?
|
| Body Composition | 5 | 2017 | 564 | 0.170 |
Why?
|
| Proprotein Convertases | 3 | 2010 | 27 | 0.170 |
Why?
|
| Diastole | 7 | 2005 | 177 | 0.170 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2019 | 51 | 0.170 |
Why?
|
| Erythrocytes | 4 | 2012 | 232 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 1148 | 0.160 |
Why?
|
| Biomarkers | 7 | 2020 | 3409 | 0.160 |
Why?
|
| Granzymes | 2 | 2010 | 48 | 0.160 |
Why?
|
| Dietary Carbohydrates | 1 | 2020 | 118 | 0.160 |
Why?
|
| CpG Islands | 3 | 2018 | 346 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 2012 | 94 | 0.160 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2019 | 17 | 0.160 |
Why?
|
| Haplotypes | 6 | 2012 | 544 | 0.160 |
Why?
|
| Chemokine CCL2 | 3 | 2012 | 121 | 0.160 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 148 | 0.150 |
Why?
|
| Age Factors | 10 | 2020 | 2950 | 0.150 |
Why?
|
| Apolipoproteins | 3 | 2015 | 72 | 0.150 |
Why?
|
| Linkage Disequilibrium | 5 | 2012 | 317 | 0.150 |
Why?
|
| Apolipoproteins E | 6 | 2012 | 202 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2016 | 3714 | 0.150 |
Why?
|
| Pericardium | 1 | 2019 | 87 | 0.150 |
Why?
|
| Apolipoprotein A-II | 1 | 2018 | 8 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 162 | 0.150 |
Why?
|
| Vascular Calcification | 1 | 2019 | 68 | 0.150 |
Why?
|
| Norepinephrine | 3 | 2013 | 168 | 0.140 |
Why?
|
| Adiposity | 2 | 2017 | 207 | 0.140 |
Why?
|
| Rest | 1 | 2018 | 66 | 0.140 |
Why?
|
| Estradiol | 2 | 2019 | 557 | 0.140 |
Why?
|
| Age of Onset | 4 | 2009 | 626 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 500 | 0.140 |
Why?
|
| Sex Factors | 9 | 2016 | 1354 | 0.140 |
Why?
|
| Lipoprotein Lipase | 3 | 2011 | 60 | 0.140 |
Why?
|
| Animals | 15 | 2022 | 35916 | 0.140 |
Why?
|
| Endothelin-1 | 1 | 2017 | 45 | 0.140 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2017 | 22 | 0.140 |
Why?
|
| Early Diagnosis | 2 | 2017 | 198 | 0.140 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2017 | 13 | 0.140 |
Why?
|
| Phytosterols | 1 | 2017 | 28 | 0.140 |
Why?
|
| Videotape Recording | 1 | 2017 | 58 | 0.140 |
Why?
|
| Weight Loss | 3 | 2017 | 516 | 0.140 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2007 | 130 | 0.140 |
Why?
|
| Fiber Optic Technology | 1 | 2017 | 46 | 0.140 |
Why?
|
| Fatty Acids | 2 | 2011 | 367 | 0.130 |
Why?
|
| Incidence | 7 | 2017 | 3376 | 0.130 |
Why?
|
| Access to Information | 1 | 2017 | 44 | 0.130 |
Why?
|
| Stroke Volume | 6 | 2020 | 529 | 0.130 |
Why?
|
| Chylomicron Remnants | 1 | 2016 | 1 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 2 | 2007 | 140 | 0.130 |
Why?
|
| Privacy | 1 | 2017 | 28 | 0.130 |
Why?
|
| Vasodilation | 4 | 2023 | 176 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2016 | 4848 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2011 | 2188 | 0.130 |
Why?
|
| Quadriceps Muscle | 1 | 2016 | 17 | 0.130 |
Why?
|
| Intestinal Diseases | 1 | 2017 | 88 | 0.130 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2016 | 18 | 0.130 |
Why?
|
| Homeostasis | 5 | 2016 | 745 | 0.130 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 84 | 0.130 |
Why?
|
| RNA, Messenger | 4 | 2016 | 2866 | 0.130 |
Why?
|
| Predictive Value of Tests | 10 | 2016 | 2314 | 0.130 |
Why?
|
| Apolipoproteins A | 4 | 2012 | 53 | 0.130 |
Why?
|
| Hyperinsulinism | 1 | 1996 | 64 | 0.120 |
Why?
|
| Machine Learning | 1 | 2020 | 348 | 0.120 |
Why?
|
| Environment | 5 | 2011 | 154 | 0.120 |
Why?
|
| Cardiovascular System | 1 | 2017 | 107 | 0.120 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2015 | 176 | 0.120 |
Why?
|
| Abdomen | 1 | 2016 | 136 | 0.120 |
Why?
|
| Lung Transplantation | 2 | 2010 | 336 | 0.120 |
Why?
|
| Potassium | 5 | 2020 | 275 | 0.120 |
Why?
|
| Genome, Human | 4 | 2007 | 1336 | 0.120 |
Why?
|
| Electrophoresis | 1 | 2015 | 50 | 0.120 |
Why?
|
| Anticholesteremic Agents | 3 | 2017 | 239 | 0.120 |
Why?
|
| Operative Time | 1 | 2016 | 189 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2016 | 73 | 0.120 |
Why?
|
| Ventricular Remodeling | 5 | 2004 | 173 | 0.120 |
Why?
|
| Resistin | 2 | 2016 | 30 | 0.120 |
Why?
|
| Laryngoscopy | 1 | 2017 | 158 | 0.120 |
Why?
|
| Fasting | 4 | 2013 | 309 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 1420 | 0.120 |
Why?
|
| Equivalence Trials as Topic | 2 | 2025 | 25 | 0.120 |
Why?
|
| Renal Circulation | 3 | 2011 | 45 | 0.120 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 159 | 0.120 |
Why?
|
| Models, Genetic | 5 | 2012 | 786 | 0.120 |
Why?
|
| Myocardial Contraction | 4 | 2004 | 253 | 0.120 |
Why?
|
| Diabetes Mellitus | 9 | 2016 | 917 | 0.120 |
Why?
|
| Epinephrine | 2 | 2013 | 165 | 0.120 |
Why?
|
| Folic Acid Deficiency | 1 | 1995 | 51 | 0.120 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2004 | 377 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2015 | 94 | 0.120 |
Why?
|
| Glucose | 2 | 2016 | 914 | 0.120 |
Why?
|
| Cadherins | 2 | 2014 | 183 | 0.120 |
Why?
|
| Thinness | 1 | 2015 | 77 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 398 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2012 | 66 | 0.110 |
Why?
|
| Iodide Peroxidase | 2 | 2021 | 10 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2015 | 392 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1037 | 0.110 |
Why?
|
| Twins | 2 | 2011 | 73 | 0.110 |
Why?
|
| Metabolomics | 1 | 2018 | 471 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 390 | 0.110 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2014 | 86 | 0.110 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 74 | 0.110 |
Why?
|
| Proteins | 2 | 2011 | 1089 | 0.110 |
Why?
|
| Intubation, Intratracheal | 1 | 2017 | 291 | 0.110 |
Why?
|
| Genetic Markers | 6 | 2009 | 622 | 0.110 |
Why?
|
| Marriage | 2 | 2011 | 28 | 0.110 |
Why?
|
| Leukocytes | 1 | 2015 | 216 | 0.110 |
Why?
|
| Computers | 1 | 2013 | 70 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2025 | 313 | 0.100 |
Why?
|
| Drug Resistance | 2 | 2012 | 262 | 0.100 |
Why?
|
| Telomere | 1 | 2015 | 228 | 0.100 |
Why?
|
| Vitamin D | 2 | 2012 | 181 | 0.100 |
Why?
|
| Lipoproteins, IDL | 2 | 2011 | 6 | 0.100 |
Why?
|
| Cholesterol, Dietary | 2 | 1992 | 48 | 0.100 |
Why?
|
| Sarcopenia | 1 | 2014 | 57 | 0.100 |
Why?
|
| Scleroderma, Systemic | 1 | 2014 | 130 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2015 | 374 | 0.100 |
Why?
|
| Dexfenfluramine | 2 | 2003 | 3 | 0.100 |
Why?
|
| Specialization | 1 | 2014 | 80 | 0.100 |
Why?
|
| Antiporters | 3 | 2004 | 35 | 0.100 |
Why?
|
| Hand | 1 | 2014 | 107 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 1 | 5 | 2010 | 150 | 0.100 |
Why?
|
| Frail Elderly | 1 | 2014 | 108 | 0.100 |
Why?
|
| Blood Glucose | 7 | 2016 | 1170 | 0.100 |
Why?
|
| Television | 1 | 2013 | 71 | 0.100 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2012 | 41 | 0.100 |
Why?
|
| Linear Models | 5 | 2014 | 718 | 0.100 |
Why?
|
| Uric Acid | 4 | 2006 | 109 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 803 | 0.100 |
Why?
|
| Iron Overload | 1 | 2012 | 16 | 0.100 |
Why?
|
| Mineralocorticoids | 1 | 2012 | 8 | 0.100 |
Why?
|
| Electrocardiography | 5 | 2005 | 996 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 677 | 0.090 |
Why?
|
| Sex Characteristics | 4 | 2017 | 335 | 0.090 |
Why?
|
| Chorion | 1 | 2011 | 9 | 0.090 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2012 | 35 | 0.090 |
Why?
|
| Physician's Role | 1 | 2014 | 171 | 0.090 |
Why?
|
| Mice, Knockout | 5 | 2022 | 3978 | 0.090 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 56 | 0.090 |
Why?
|
| Genetic Association Studies | 5 | 2016 | 859 | 0.090 |
Why?
|
| Echocardiography | 11 | 2006 | 1129 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 567 | 0.090 |
Why?
|
| Hostility | 2 | 2011 | 21 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 3047 | 0.090 |
Why?
|
| Divorce | 1 | 2011 | 6 | 0.090 |
Why?
|
| Adipocytes | 1 | 2012 | 178 | 0.090 |
Why?
|
| Calcifediol | 1 | 2011 | 15 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2007 | 65 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2011 | 115 | 0.090 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 50 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2016 | 520 | 0.090 |
Why?
|
| Family | 4 | 2015 | 596 | 0.090 |
Why?
|
| Pinch Strength | 1 | 2010 | 5 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2001 | 88 | 0.090 |
Why?
|
| Amputation, Traumatic | 1 | 2010 | 11 | 0.080 |
Why?
|
| C-Reactive Protein | 4 | 2012 | 469 | 0.080 |
Why?
|
| Comorbidity | 5 | 2004 | 1609 | 0.080 |
Why?
|
| Risk | 3 | 2012 | 767 | 0.080 |
Why?
|
| Thumb | 1 | 2010 | 30 | 0.080 |
Why?
|
| Sex | 1 | 2010 | 7 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2011 | 186 | 0.080 |
Why?
|
| Lipase | 2 | 2007 | 97 | 0.080 |
Why?
|
| Replantation | 1 | 2010 | 57 | 0.080 |
Why?
|
| Hyperlipoproteinemias | 2 | 2007 | 2 | 0.080 |
Why?
|
| Smoking | 5 | 2008 | 945 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1248 | 0.080 |
Why?
|
| Calcium | 1 | 2015 | 1085 | 0.080 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2010 | 70 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 574 | 0.080 |
Why?
|
| Microsatellite Repeats | 5 | 2003 | 238 | 0.080 |
Why?
|
| Iron | 1 | 2012 | 303 | 0.080 |
Why?
|
| Stress, Psychological | 3 | 2006 | 577 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2012 | 396 | 0.080 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2009 | 41 | 0.080 |
Why?
|
| Mice | 8 | 2022 | 18888 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 233 | 0.080 |
Why?
|
| Delivery, Obstetric | 1 | 2011 | 261 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2009 | 76 | 0.080 |
Why?
|
| Social Dominance | 1 | 2008 | 11 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2013 | 572 | 0.070 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2011 | 111 | 0.070 |
Why?
|
| Lithium | 2 | 2004 | 71 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 674 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 625 | 0.070 |
Why?
|
| Supine Position | 2 | 2005 | 25 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 636 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2015 | 259 | 0.070 |
Why?
|
| Personality | 2 | 2008 | 114 | 0.070 |
Why?
|
| Posture | 2 | 2005 | 154 | 0.070 |
Why?
|
| Personality Assessment | 1 | 2008 | 111 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 211 | 0.070 |
Why?
|
| Heart Failure | 2 | 2020 | 2413 | 0.070 |
Why?
|
| Hydrocortisone | 3 | 2012 | 243 | 0.070 |
Why?
|
| Apolipoprotein A-I | 3 | 2020 | 89 | 0.070 |
Why?
|
| Heart Function Tests | 2 | 2005 | 55 | 0.070 |
Why?
|
| Reference Values | 4 | 2001 | 724 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2006 | 149 | 0.070 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2007 | 27 | 0.070 |
Why?
|
| Receptors, Chemokine | 1 | 2007 | 47 | 0.070 |
Why?
|
| Vascular Resistance | 4 | 2007 | 197 | 0.070 |
Why?
|
| Affect | 1 | 2008 | 173 | 0.070 |
Why?
|
| Vasculitis | 1 | 2007 | 50 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 94 | 0.070 |
Why?
|
| Quantitative Trait Loci | 2 | 2006 | 314 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2004 | 34 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2007 | 102 | 0.070 |
Why?
|
| Gene Expression | 3 | 2016 | 1598 | 0.070 |
Why?
|
| Child | 14 | 2017 | 25889 | 0.060 |
Why?
|
| Postmenopause | 1 | 2007 | 154 | 0.060 |
Why?
|
| Introns | 1 | 2007 | 316 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2003 | 728 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 198 | 0.060 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2006 | 52 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 1583 | 0.060 |
Why?
|
| Isometric Contraction | 1 | 2005 | 24 | 0.060 |
Why?
|
| Glutamate Decarboxylase | 1 | 2006 | 42 | 0.060 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 2 | 2017 | 26 | 0.060 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 248 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2017 | 332 | 0.060 |
Why?
|
| Genes, Dominant | 3 | 2019 | 252 | 0.060 |
Why?
|
| Lovastatin | 1 | 2005 | 23 | 0.060 |
Why?
|
| Homozygote | 3 | 2012 | 560 | 0.060 |
Why?
|
| Linolenic Acids | 1 | 2005 | 2 | 0.060 |
Why?
|
| Medical History Taking | 2 | 2001 | 114 | 0.060 |
Why?
|
| alpha-Linolenic Acid | 1 | 2005 | 16 | 0.060 |
Why?
|
| Energy Metabolism | 2 | 2017 | 813 | 0.060 |
Why?
|
| Atrial Function, Left | 1 | 2005 | 29 | 0.060 |
Why?
|
| Coma | 1 | 2025 | 57 | 0.060 |
Why?
|
| Myocardium | 2 | 2016 | 914 | 0.060 |
Why?
|
| Linoleic Acid | 1 | 2005 | 19 | 0.060 |
Why?
|
| Point Mutation | 2 | 2004 | 353 | 0.060 |
Why?
|
| Sympathetic Nervous System | 2 | 2013 | 62 | 0.060 |
Why?
|
| Tripartite Motif Proteins | 2 | 2015 | 20 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2025 | 13069 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2006 | 249 | 0.060 |
Why?
|
| Heart Rate | 3 | 2005 | 581 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 1169 | 0.060 |
Why?
|
| Cluster Analysis | 3 | 2011 | 435 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2005 | 166 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 1704 | 0.050 |
Why?
|
| Cytokines | 1 | 2010 | 1374 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2009 | 794 | 0.050 |
Why?
|
| Heart Conduction System | 1 | 2005 | 145 | 0.050 |
Why?
|
| Hyperuricemia | 1 | 2004 | 41 | 0.050 |
Why?
|
| Organ Size | 3 | 2014 | 458 | 0.050 |
Why?
|
| Chromosome Segregation | 2 | 2001 | 68 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 32 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2003 | 56 | 0.050 |
Why?
|
| Proteolysis | 2 | 2015 | 200 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2017 | 3124 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2003 | 82 | 0.050 |
Why?
|
| Body Weight | 4 | 2017 | 1023 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 2020 | 450 | 0.050 |
Why?
|
| Quality of Life | 2 | 2012 | 2159 | 0.050 |
Why?
|
| Rats | 2 | 2015 | 3686 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2005 | 207 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2023 | 96 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 95 | 0.050 |
Why?
|
| Rats, Inbred Strains | 1 | 2002 | 223 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2018 | 462 | 0.050 |
Why?
|
| Bias | 1 | 2003 | 145 | 0.050 |
Why?
|
| Phentermine | 1 | 2002 | 7 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2003 | 188 | 0.050 |
Why?
|
| Appetite Depressants | 1 | 2002 | 23 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 1999 | 71 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 145 | 0.050 |
Why?
|
| Stroke | 3 | 2005 | 1078 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2016 | 17493 | 0.050 |
Why?
|
| Arousal | 1 | 2002 | 82 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 2 | 2012 | 171 | 0.050 |
Why?
|
| Apolipoprotein A-V | 2 | 2012 | 23 | 0.050 |
Why?
|
| Muscle Proteins | 2 | 2015 | 418 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2021 | 21 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4725 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 1765 | 0.050 |
Why?
|
| Aorta | 1 | 2005 | 555 | 0.040 |
Why?
|
| Carrier Proteins | 3 | 2004 | 1071 | 0.040 |
Why?
|
| Lysine | 1 | 2022 | 207 | 0.040 |
Why?
|
| Lisinopril | 1 | 2001 | 22 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 71 | 0.040 |
Why?
|
| Sinus of Valsalva | 1 | 2001 | 35 | 0.040 |
Why?
|
| Nuclear Family | 2 | 2001 | 51 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2005 | 359 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 569 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2001 | 115 | 0.040 |
Why?
|
| Child, Preschool | 7 | 2017 | 14906 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2020 | 45 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 73 | 0.040 |
Why?
|
| Tangier Disease | 1 | 2000 | 6 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2020 | 39 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2003 | 398 | 0.040 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2011 | 19 | 0.040 |
Why?
|
| Genes | 3 | 1996 | 446 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 79 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 107 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2010 | 150 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2019 | 73 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2020 | 254 | 0.040 |
Why?
|
| Life Style | 3 | 2011 | 457 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 221 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2005 | 727 | 0.040 |
Why?
|
| Liver | 2 | 2017 | 1852 | 0.040 |
Why?
|
| Genetic Heterogeneity | 3 | 2007 | 142 | 0.040 |
Why?
|
| Probability | 2 | 2004 | 328 | 0.040 |
Why?
|
| Ultrasonography | 3 | 2014 | 998 | 0.040 |
Why?
|
| Epistasis, Genetic | 2 | 2012 | 103 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 679 | 0.040 |
Why?
|
| Primary Prevention | 1 | 1999 | 178 | 0.040 |
Why?
|
| Zona Glomerulosa | 1 | 2017 | 3 | 0.040 |
Why?
|
| Graft Survival | 2 | 2010 | 482 | 0.040 |
Why?
|
| Fatty Acid Desaturases | 1 | 2017 | 9 | 0.040 |
Why?
|
| Siblings | 2 | 2012 | 202 | 0.040 |
Why?
|
| Sitosterols | 1 | 2017 | 10 | 0.040 |
Why?
|
| Likelihood Functions | 3 | 2004 | 120 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 544 | 0.030 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2017 | 11 | 0.030 |
Why?
|
| Diet, Fat-Restricted | 1 | 2017 | 40 | 0.030 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2017 | 42 | 0.030 |
Why?
|
| Respiratory Rate | 1 | 2017 | 7 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2010 | 813 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2018 | 252 | 0.030 |
Why?
|
| Exons | 2 | 2012 | 823 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 3094 | 0.030 |
Why?
|
| Ezetimibe | 1 | 2017 | 94 | 0.030 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2016 | 16 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 591 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2016 | 14 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1419 | 0.030 |
Why?
|
| Aldehyde Reductase | 1 | 2016 | 17 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 309 | 0.030 |
Why?
|
| Spironolactone | 1 | 2016 | 20 | 0.030 |
Why?
|
| Multigene Family | 2 | 2007 | 321 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 2144 | 0.030 |
Why?
|
| Sex Distribution | 3 | 2002 | 326 | 0.030 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 41 | 0.030 |
Why?
|
| Resistance Training | 1 | 2016 | 32 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 1996 | 42 | 0.030 |
Why?
|
| Extremities | 1 | 2016 | 87 | 0.030 |
Why?
|
| Laryngoscopes | 1 | 2017 | 70 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2016 | 86 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 98 | 0.030 |
Why?
|
| Graft Rejection | 2 | 2010 | 566 | 0.030 |
Why?
|
| Base Sequence | 3 | 1996 | 3147 | 0.030 |
Why?
|
| Energy Intake | 2 | 2011 | 515 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1504 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 177 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2007 | 1018 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 1999 | 1825 | 0.030 |
Why?
|
| Time Factors | 3 | 2015 | 6526 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1653 | 0.030 |
Why?
|
| Pyridoxine | 1 | 1995 | 15 | 0.030 |
Why?
|
| Renal Artery | 1 | 1996 | 68 | 0.030 |
Why?
|
| Body Constitution | 2 | 2001 | 42 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 439 | 0.030 |
Why?
|
| Amino Acids, Essential | 1 | 2015 | 28 | 0.030 |
Why?
|
| Bed Rest | 1 | 2015 | 22 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 605 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 1995 | 63 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1996 | 3937 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 2015 | 219 | 0.030 |
Why?
|
| Survivors | 1 | 1997 | 358 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 454 | 0.030 |
Why?
|
| Angiography | 1 | 2015 | 213 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2716 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 420 | 0.030 |
Why?
|
| Apolipoprotein E2 | 2 | 1991 | 15 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 256 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 284 | 0.030 |
Why?
|
| Suicide | 1 | 2017 | 202 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 280 | 0.030 |
Why?
|
| Walking | 1 | 2016 | 233 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 260 | 0.030 |
Why?
|
| Binding Sites | 3 | 2012 | 1360 | 0.030 |
Why?
|
| p-Aminohippuric Acid | 1 | 2014 | 5 | 0.030 |
Why?
|
| DNA | 4 | 2012 | 1671 | 0.030 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2014 | 21 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2014 | 30 | 0.030 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2014 | 10 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 16 | 0.030 |
Why?
|
| Dynamins | 1 | 2014 | 44 | 0.030 |
Why?
|
| Electrolytes | 2 | 1991 | 54 | 0.030 |
Why?
|
| Neoplasms | 1 | 2009 | 2975 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1314 | 0.030 |
Why?
|
| Vitamins | 1 | 1994 | 113 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2013 | 76 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2014 | 69 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 446 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2015 | 184 | 0.030 |
Why?
|
| Folic Acid | 1 | 1995 | 291 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 170 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2014 | 90 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 215 | 0.020 |
Why?
|
| Orthopedics | 1 | 2014 | 78 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2005 | 111 | 0.020 |
Why?
|
| Exome | 1 | 2018 | 1085 | 0.020 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 155 | 0.020 |
Why?
|
| Trans Fatty Acids | 1 | 2012 | 11 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 2246 | 0.020 |
Why?
|
| Hemochromatosis Protein | 1 | 2012 | 23 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2012 | 20 | 0.020 |
Why?
|
| Iron, Dietary | 1 | 2012 | 17 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2012 | 58 | 0.020 |
Why?
|
| Potassium, Dietary | 1 | 2012 | 13 | 0.020 |
Why?
|
| Minnesota | 1 | 2012 | 181 | 0.020 |
Why?
|
| Hemochromatosis | 1 | 2012 | 38 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 1111 | 0.020 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 99 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 256 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2011 | 6579 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1464 | 0.020 |
Why?
|
| Ferritins | 1 | 2012 | 109 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2012 | 93 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 107 | 0.020 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 2011 | 2 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 392 | 0.020 |
Why?
|
| Cation Transport Proteins | 1 | 2012 | 100 | 0.020 |
Why?
|
| Perinatal Mortality | 1 | 2011 | 44 | 0.020 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 110 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 696 | 0.020 |
Why?
|
| Syndrome | 5 | 1994 | 1173 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 141 | 0.020 |
Why?
|
| Hypobetalipoproteinemias | 1 | 1991 | 4 | 0.020 |
Why?
|
| General Surgery | 1 | 2014 | 220 | 0.020 |
Why?
|
| Dominance-Subordination | 1 | 2011 | 11 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 130 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 1992 | 140 | 0.020 |
Why?
|
| Azathioprine | 1 | 2010 | 38 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2011 | 180 | 0.020 |
Why?
|
| Genome | 2 | 2005 | 527 | 0.020 |
Why?
|
| Prednisolone | 1 | 2010 | 73 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 123 | 0.020 |
Why?
|
| Finger Injuries | 1 | 2010 | 23 | 0.020 |
Why?
|
| Age Distribution | 2 | 2002 | 437 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 1587 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2198 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 330 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2010 | 48 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 622 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 146 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 412 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2010 | 61 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2010 | 128 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1663 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2010 | 105 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 428 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2010 | 173 | 0.020 |
Why?
|
| Pregnancy | 3 | 2011 | 7593 | 0.020 |
Why?
|
| Euthanasia, Passive | 1 | 2009 | 9 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2009 | 52 | 0.020 |
Why?
|
| Ethics Committees, Clinical | 1 | 2009 | 18 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1059 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2012 | 816 | 0.020 |
Why?
|
| Twins, Dizygotic | 1 | 1989 | 47 | 0.020 |
Why?
|
| Prognosis | 2 | 2014 | 5043 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2009 | 54 | 0.020 |
Why?
|
| Policy Making | 1 | 2009 | 61 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 252 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 11 | 0.020 |
Why?
|
| Skinfold Thickness | 2 | 2003 | 34 | 0.020 |
Why?
|
| Anger | 1 | 2008 | 30 | 0.020 |
Why?
|
| Twins, Monozygotic | 1 | 1989 | 128 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2009 | 173 | 0.020 |
Why?
|
| Death | 1 | 2009 | 80 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 341 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 259 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 535 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2010 | 373 | 0.020 |
Why?
|
| Self Report | 1 | 2011 | 553 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 311 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 137 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1993 | 1973 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 452 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 1230 | 0.020 |
Why?
|
| Osteonectin | 1 | 2007 | 6 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 510 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 2007 | 83 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 102 | 0.020 |
Why?
|
| Reoperation | 1 | 2010 | 856 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 545 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 102 | 0.020 |
Why?
|
| Public Health | 1 | 1989 | 284 | 0.020 |
Why?
|
| France | 1 | 2006 | 89 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 59 | 0.020 |
Why?
|
| Hypokalemia | 1 | 2006 | 41 | 0.020 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2005 | 9 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2007 | 336 | 0.010 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2005 | 32 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2005 | 32 | 0.010 |
Why?
|
| Growth | 1 | 2005 | 106 | 0.010 |
Why?
|
| Palliative Care | 1 | 2009 | 461 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1455 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2008 | 481 | 0.010 |
Why?
|
| Progesterone | 1 | 2007 | 635 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2005 | 68 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 330 | 0.010 |
Why?
|
| Hormones | 1 | 2005 | 197 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 303 | 0.010 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2005 | 83 | 0.010 |
Why?
|
| Overweight | 1 | 2007 | 387 | 0.010 |
Why?
|
| Thioredoxins | 1 | 2004 | 26 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 136 | 0.010 |
Why?
|
| Thyroxine | 1 | 2004 | 70 | 0.010 |
Why?
|
| Infant | 2 | 2017 | 13258 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 805 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 136 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2003 | 138 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 4818 | 0.010 |
Why?
|
| Heart Atria | 1 | 2005 | 334 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 1566 | 0.010 |
Why?
|
| Kallikreins | 2 | 1993 | 31 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 733 | 0.010 |
Why?
|
| Diseases in Twins | 2 | 1993 | 99 | 0.010 |
Why?
|
| Body Surface Area | 1 | 2002 | 35 | 0.010 |
Why?
|
| Disease Susceptibility | 2 | 1996 | 294 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2001 | 44 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2002 | 163 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2001 | 103 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2002 | 278 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 2001 | 3 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 232 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2001 | 26 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 2000 | 11 | 0.010 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2001 | 53 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 907 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2002 | 200 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2000 | 46 | 0.010 |
Why?
|
| Long QT Syndrome | 1 | 2001 | 85 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2001 | 190 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 1999 | 42 | 0.010 |
Why?
|
| Penetrance | 1 | 2000 | 113 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 415 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2004 | 940 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 2156 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8633 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2010 | 3171 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1728 | 0.010 |
Why?
|
| Eating | 1 | 2000 | 388 | 0.010 |
Why?
|
| Genomics | 1 | 2006 | 1670 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1997 | 189 | 0.010 |
Why?
|
| Environmental Health | 1 | 1994 | 16 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 1994 | 43 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1993 | 54 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1994 | 256 | 0.010 |
Why?
|
| Paris | 1 | 1992 | 11 | 0.010 |
Why?
|
| Apolipoprotein E3 | 1 | 1991 | 6 | 0.010 |
Why?
|
| Caffeine | 1 | 1991 | 64 | 0.010 |
Why?
|
| Ouabain | 1 | 1991 | 22 | 0.010 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 1991 | 37 | 0.010 |
Why?
|
| Phosphates | 1 | 1991 | 117 | 0.010 |
Why?
|
| Cooking | 1 | 1991 | 38 | 0.010 |
Why?
|
| Job Satisfaction | 1 | 1991 | 99 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 1991 | 186 | 0.010 |
Why?
|
| Educational Status | 1 | 1991 | 295 | 0.010 |
Why?
|
| Nutritional Sciences | 1 | 1991 | 76 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1991 | 195 | 0.010 |
Why?
|
| Forecasting | 1 | 1991 | 374 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 494 | 0.000 |
Why?
|
| Self Care | 1 | 1991 | 228 | 0.000 |
Why?
|
| Alcohol Drinking | 1 | 1991 | 361 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1990 | 834 | 0.000 |
Why?
|
| Social Environment | 1 | 1989 | 122 | 0.000 |
Why?
|
| Patient Education as Topic | 1 | 1991 | 466 | 0.000 |
Why?
|
| Biological Transport | 1 | 1988 | 363 | 0.000 |
Why?
|
| Texas | 1 | 1992 | 3658 | 0.000 |
Why?
|